Nanodelivery of FP polymers to improve treatment of metastatic colorectal cancer
Funded at Wake Forest University Health Sciences · NIH-11365062 · Data updated 2026-11-12
A new nanoscale therapy called CF10 is being developed to deliver a chemotherapy drug more directly to metastatic colorectal cancer, aiming for better tumor targeting and fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wake Forest University Health Sciences NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $577,559 |
| NIH project number | 5R01CA284083-04 |
| Project ID | NIH-11365062 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be adults with metastatic colorectal cancer who are eligible for experimental nanoparticle-based therapies.
✕Less likely to help
Patients without metastatic colorectal cancer or those unable to participate in early-phase nanomedicine studies may not benefit.
What this research studies
This project aims to make a chemotherapy drug (CF10) reach metastatic colorectal cancer more effectively by packaging it in lipid nanoparticles. Researchers will test two CF10-LNP formulations to direct the drug to liver and metastatic sites while keeping it stable in blood. They will also explore attaching a targeting molecule that binds to tumor cells, potentially increasing precision. The study combines nanotechnology, chemistry, and cancer biology to move CF10 closer to clinical use. If successful, this approach could offer a more active and selective treatment option for patients with advanced colorectal cancer.
Why it matters
Potential benefit: If successful, patients with metastatic colorectal cancer could receive a more effective and targeted therapy with fewer side effects.
How similar studies have gone: Previous nanoparticle delivery approaches have shown promise in targeting tumors, but this specific CF10-LNP strategy is being tested for improved delivery and activity.
Where this research is happening
-
Wake Forest University Health Sciences
Winston-Salem, United States Active
Researchers
- Principal investigator: Gmeiner, William H. — Wake Forest University Health Sciences
- Study coordinator: Gmeiner, William H.
Related research
Other NIH-funded projects on the same topics.
-
Population-based view of patient-reported outcomes in adults with metastatic colorectal cancer
This grant funds a long-term study to understand experiences and quality of life for adults living with metastatic colorectal cancer.
-
How metastatic colorectal cancer weakens muscles and bones
This research looks at how metastatic colorectal cancer and a hormone called FGF21 cause muscle and bone wasting in people with advanced colorectal cancer.
-
Nanoscale polymers delivering patient-specific cancer vaccines for metastatic colorectal cancer
A new therapy uses tiny, designer particles to carry patient-specific cancer antigens to tumors in people with advanced colorectal cancer.
-
Targeted nanoparticles combining chemotherapy and immune stimulation for advanced colon cancer
Targeted nanoparticles that deliver a two-drug chemotherapy combo plus immune-activating components are being developed to help people with metastatic colorectal (colon) cancer that usually does not respond to current immunotherapy.
-
Symptoms and quality of life in adults living with metastatic colorectal cancer
Researchers will follow adults with metastatic colorectal cancer over time to learn what symptoms and quality-of-life issues they experience during treatment and survivorship.
-
miR-15a microRNA therapy for advanced metastatic colorectal cancer
A new treatment using a small RNA called miR-15a is being developed to help people, including Veterans, with advanced metastatic colorectal cancer that is resistant to standard chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.